Drug intelligence / Profile preview

Pure Femme Tablets

Development stage: Phase 2
Lead developer: Pure Green Pharmaceuticals
Modality: Small Molecules
Administration: Sublingual

Overview

Pure Femme Tablets is a sublingual tablet developed by Pure Green, designed for the treatment of dysmenorrhea and associated pain symptoms. It is a combination drug containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene, along with peppermint oil.

Brand names: Pure Femme Tablets

Targets

CNR1 (Cannabinoid receptor 1)PPARG (Peroxisome proliferator-activated receptor gamma)ER (Estrogen receptor)TRPV1 (Transient receptor potential cation channel subfamily V member 1)GPR55 (G protein-coupled receptor 55)FAAHPR (Progesterone receptor)

Beyond the preview

Go deeper on Pure Femme Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pure Femme Tablets.

Explore the full profile